Urteste SA

Chart & Performance

D1W1MN

P/E

—

P/S

3,329.63

EPS

—

Div Yield, %

—

Shrs. gr., 5y

18.84%

Rev. gr., 5y

Revenues

22k

-98.78%

Net income

-6m

L+64.72%

CFO

11m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Urteste S.A. focuses on the investigation and development of diagnostic solutions designed to detect various forms of cancer. Their portfolio includes testing methods for a wide range of malignancies affecting organs such as the pancreas, prostate, kidneys, colon, liver, biliary system, stomach, lungs, esophagus, ovaries, endometrium, blood, breasts, and the nervous system. This enterprise, based in Gdansk, Poland, commenced its operations in 2021.

URL

https://urteste.eu/

IPO date

Oct 27, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title PLN in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title PLN in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT